NBIX

#767
Neurocrine Biosciences Inc
130.8100 USD
+3.55%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
130.8100
130.8100
Intervallo Annuale
122.1375
160.1800
Variazione giornaliera
+3.55%
Variazione Mensile
+0.31%
Variazione di 6 mesi
-9.79%
Variazione Annuale
-9.79%
Chiusura Precedente
126.3200
Apertura
130.8100
Bid
Ask
Minimo
130.8100
High
130.8100
Volume
127
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 13.1285 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
30.37
Rapporto prezzo/fatturato
5.08

Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Notizie